The iShares Biotech exchange-traded fund, which tracks a broad basket of industry leaders, dipped 0.9% during the session. Despite this pullback, the fund continues to trade near all-time highs. The recent cooling follows a period of intense enthusiasm, as investors previously poured capital into firms promising new breakthroughs in cancer treatment and weight-loss therapeutics. This shift in sentiment underscores a broader trend of market caution as participants re-evaluate valuations in the face of recent rapid growth.
Biotech Stocks Slip as Investors Shed Risky Positions
A sudden retreat from high-risk biotechnology and obesity-drug manufacturers dragged health-care stocks lower today. While the sector has enjoyed a sustained rally fueled by oncology breakthroughs and feverish merger activity, traders are now opting to lock in profits rather than chase further gains in the volatile sub-sector.
Comments (0)
No comments yet. Be the first!